Licari Amelia, Castagnoli Riccardo, Panfili Elisa, Marseglia Alessia, Brambilla Ilaria, Marseglia Gian Luigi
Department of Pediatrics, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy.
Institute of Paediatrics, Department of Biomedical and Surgical Specialties, University of Perugia, Perugia, Italy.
Curr Respir Med Rev. 2017 Mar;13(1):22-29. doi: 10.2174/1573398X13666170616110738.
Anti-IgE treatment represents a major breakthrough in the therapeutic management of severe allergic asthma. Omalizumab is the unique biologic treatment registered for asthma therapy in children. The clinical efficacy and safety of omalizumab treatment in the pediatric population has been extensively documented in specific trials and consistently expanded from real-life studies. In addition, new experimental evidence suggests that omalizumab may also interfere with the cellular and molecular mechanisms underlying airway remodeling. Novel investigational anti-IgE monoclonal antibodies with improved pharmacodynamic properties are in the pipeline, potentially offering alternative mechanisms of modulating IgE pathway. The aim of this review is to update current knowledge on anti-IgE therapy in pediatric respiratory diseases.
抗IgE治疗是重度过敏性哮喘治疗管理方面的一项重大突破。奥马珠单抗是唯一获批用于儿童哮喘治疗的生物制剂。奥马珠单抗治疗在儿科人群中的临床疗效和安全性已在特定试验中得到广泛记录，并且在真实世界研究中持续得到拓展。此外，新的实验证据表明奥马珠单抗可能还会干扰气道重塑的细胞和分子机制。具有改善药效学特性的新型抗IgE单克隆抗体正在研发中，有望提供调节IgE通路的替代机制。本综述的目的是更新有关儿科呼吸系统疾病抗IgE治疗的现有知识。
